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to conclude that many patients receiving long-term ACE inhibi-
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REPLY
Thank you for your comments. At issue is not primarily the
long-term effects of aspirin in coronary artery disease but its
combination with an angiotensin-converting enzyme (ACE) in-
hibitor in patients with heart failure (1). Any real benefits of
long-term aspirin therapy, however, have been regarded, at best, as
questionable. The meta-analysis (1) on which your argument is
based is characterized by important weaknesses and shortcomings
which Dr. Cleland has done a good job of pointing out (2).
I am sure that no responsible physician wants to deny patients
drugs of proven benefit. However, the negation of an interaction (3)
based on results of the use of otherwise effective heart failure drugs
which, in 90,000 patients taking the combination of an ACE
inhibitor with aspirin, did conspicuously little or nothing is a
benefit with which some physicians are not content. There was not
even prevention of heart failure. Moreover, in the most recent
meta-analysis cited (4) in your letter in which, similar to that of
Latini et al. (3), the patient groups are dissimilar, there was a
consistently more favorable risk reduction in patients without
aspirin (0.85 vs. 0.75 and 0.76 vs. 0.68 for death and combined
death, heart failure and myocardial infarction in the aspirin vs. no
aspirin groups, respectively). Consequently, in consideration of the
comparative yield of the combination of an ACE inhibitor and
aspirin and an ACE inhibitor without aspirin (Table 1 of reference
[5]), it appears, rather, that with the combination, we are denying
many patients an effective treatment for heart failure.
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Papillary Muscle Hypothesis of
Idiopathic Left Ventricular Tachycardia
Nogami et al. (1) recently demonstrated that diastolic (P1) and
presystolic (P2) Purkinje potentials are critical potentials in a
macroreentry circuit of verapamil-sensitive idiopathic left ventric-
ular tachycardia. The authors posit that P1 represents the activa-
tion potential in the distal portion of the specialized Purkinje tissue
and P2 represents the activation potential of the left posterior
fascicle. There was no mentioning of the papillary muscle as a
possible source of these potentials.
In most parts of the ventricular endocardium, Purkinje poten-
tials and myocardial potentials are nonseparable. This is not true at
the papillary muscle, where Purkinje potentials and ventricular
muscle potentials are widely separated (2,3). Joyner et al. (2)
reported that pacing from a Purkinje strand inserting into the apex
of the papillary muscle results in apex to base Purkinje activation.
The activation then excites the ventricular muscle via the Purkinje
ventricular muscle junction at the base of the papillary muscle, and
propagates from base of the papillary muscle to the apex of the
papillary muscle. The resulting activation sequence shown in
Figure 1B of that article is identical to the sequence of activation
shown in Figure 2 of the study of Nogami et al. (1). The Purkinje
strands (fibromuscular band or false tendon), which are often seen
in dogs, are also found commonly in humans, especially among
patients with idiopathic left ventricular tachycardia (4).
The safety factor of propagation from Purkinje to ventricular
muscle is lower than that from the ventricular muscle to the
Purkinje fibers (2,5). This asymmetrical safety factor of propaga-
tion may contribute to the occurrence of unidirectional block and
reentry. The papillary muscle may serve as an anchor to reentrant
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